Postoperative pain management

Goh, Shyan; Corke, Philip

doi:10.18773/austprescr.2014.039

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, oxycodone/naloxone CR has potential (although unproven) abuse‐deterrent properties . Consequently, recent reports suggest that several Australian pain services are now prescribing oxycodone/naloxone CR in preference to other formulations . However, given the observed decline in use of the tamper‐resistant single‐ingredient oxycodone CR, it is likely that much of the increased uptake of oxycodone/naloxone CR is related to its effects on opioid‐induced constipation.…”

Section: Discussionmentioning

confidence: 99%

“…18 Consequently, recent reports suggest that several Australian pain services are now prescribing oxycodone/naloxone CR in preference to other formulations. [19][20][21] However, given the observed decline in use of the tamper-resistant single-ingredient oxycodone CR, it is likely that much of the increased uptake of oxycodone/naloxone CR is related to its effects on opioid-induced constipation. Indeed, the observed uptake of oxycodone/naloxone CR was greatest in older individuals, who often On the basis of the rapid uptake of oxycodone/naloxone CR, there appears to be a real or perceived need for opioids that reduce the risk of constipation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increases in controlled‐release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population‐based study

Schaffer

Karanges

Buckley

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose Despite increasing use of oxycodone/naloxone controlled-release (CR) in Australia, little is known about how it has affected the overall oxycodone CR market since its subsidy in 2011. Methods We used Pharmaceutical Benefits Scheme dispensing claims (2006–2016) and interrupted time series analysis to examine changes in the quarterly rates of dispensing of oral oxycodone CR formulations (oxycodone/naloxone CR and single-ingredient oxycodone CR) and new oxycodone CR treatment episodes. We also performed a retrospective cohort study in a sample of people initiating a new oxycodone CR treatment episode in 2009, 2012/13 and 2016 to compare opioid utilisation patterns over time. Results The subsidy of oxycodone/naloxone CR was associated with a 1.6-fold increase in the growth rate of oxycodone CR dispensing, resulting from rapid uptake of low strength (≤5 mg) oxycodone/naloxone CR. In our cohort of initiators, the number of new oxycodone CR treatment episodes increased 2.1-fold between 2009 and 2016; in 2016, 91.4% of new treatment episodes involved oxycodone/naloxone CR. Comparing 2016 to 2009, we observed an increase in people initiating with a tablet strength ≤5 mg (Risk difference (RD) = 21.1%, 95% CI 19.9%−22.4%), in people initiating with no other opioid dispensing 90 days prior to initiation (RD = 5.2%, 3.8%−6.6%), and with no further opioid dispensing 90 days after initiation (RD = 8.8%, 7.4%−10.2%). Conclusions After its subsidy, the uptake of low-dose oxycodone/naloxone CR was greater than expected if it were substituting the single-ingredient oxycodone CR, resulting in an expansion of the oxycodone CR market.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%